Cerebral white matter demyelinating disease is clinically classified into three main levels, with less severe changes in level I and relatively more severe changes in levels II and III. Grade I demyelinating disease of the cerebral white matter mostly occurs due to ischemia and hypoxia of the cerebral white matter, resulting in malnutrition, and patients do not have clinical symptoms. Secondary and tertiary changes of cerebral white matter demyelination are generally considered to have severe ischemia and hypoxia, and as the disease progresses and worsens, the person may experience memory loss and slow response in severe cases. The main treatment is to improve the nutritional status of the white matter of the brain, and to avoid smoking, alcohol consumption and other risk factors that can increase cerebral atherosclerosis. If the patient’s memory loss is obvious, he or she can take appropriate oral medications to improve brain cell metabolism, such as olanzapine, piracetam, cerebroprotein hydrolysate tablets and cytarabine sodium tablets, which are commonly used in clinical practice.